CathWorks Announces Events for EuroPCR 2025
CathWorks, a prominent name in digital health innovation, has revealed its schedule for the upcoming EuroPCR 2025 conference. This significant event is set to take place at the Palais des Congrès in Paris and will be a showcase for groundbreaking advancements in cardiovascular health. The company aims to spotlight its FFRangio system, which is transforming the standards of patient care.
Scientific Presentation Highlights
One of the focal points during the conference will be a presentation by Dr. Toru Tanigaki. He will share insightful one-year results from the PROVISION Study—a landmark trial comparing the efficacy of FFRangio guidance with traditional invasive FFR guidance. This study has gained notable attention for its pioneering approach and significant findings regarding patient care.
Impact on the Cardiovascular Community
During the recent TCT conference, it was reported that the PROVISION Study not only met its primary endpoint but also highlighted the efficiency of FFRangio technology over conventional methods. This advancement has opened doors for deeper discussions on integrating such technologies into clinical practices to improve patient outcomes.
Engaging Educational Symposium
An Educational Symposium will also take place, titled "The New Global Era of Patient Care with CathWorks FFRangio." This session will feature several distinguished speakers, including Dr. Rasha Al-Lamee as the Anchorperson and Professor Ran Kornowski as the Spokesperson. Attendees can look forward to compelling discussions on adapting the FFRangio System into standard hospital practices.
Innovative Demonstrations and Peer Education
At the conference, the FFRangio System will be available for hands-on demonstrations. This interactive approach aims to educate physicians about the technology's potential in improving diagnostic processes. Leading experts will host guided sessions aimed at fostering collaboration across the cardiology community.
Statement from CathWorks’ Leadership
Ramin Mousavi, CEO of CathWorks, expressed enthusiasm about their collaboration with Medtronic, noting that this partnership has resulted in rapid adoption of the FFRangio system in catheterization labs worldwide. The goal moving forward is to establish FFRangio as the global standard of care in cardiovascular treatment.
About CathWorks
CathWorks is at the forefront of digital health innovation, dedicated to enhancing patient lives through advanced medical technologies. The FFRangio System blends artificial intelligence and sophisticated computational techniques to revolutionize cardiovascular diagnostics. By utilizing everyday angiograms for physiologic data, this technology eliminates unnecessary invasive procedures and provides crucial real-time data for medical decisions.
The company is committed to ensuring that healthcare providers have access to tools that improve patient care efficiently.
Frequently Asked Questions
What is the EuroPCR 2025 conference?
The EuroPCR 2025 conference is a key event focused on advancements in cardiovascular treatment and technology, where experts share innovative research and practices.
What will CathWorks present at EuroPCR?
CathWorks will present significant findings from their FFRangio study and conduct educational symposiums to demonstrate the integration of their technology into patient care.
Who are the key speakers during the CathWorks symposium?
Notable speakers include Dr. Rasha Al-Lamee and Professor Ran Kornowski, along with other distinguished experts in the field of cardiology.
How does the FFRangio System work?
The FFRangio System uses artificial intelligence to derive physiologic data from standard angiograms, improving diagnostic accuracy without invasive procedures.
What is CathWorks’ mission?
CathWorks aims to innovate healthcare solutions that enhance the quality and efficiency of cardiovascular treatment globally.
